Technical Analysis for ARWR - Arrowhead Research Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Slingshot Bearish | Bearish Swing Setup | -0.50% | |
Bullish Engulfing | Bullish | -0.50% | |
Stochastic Buy Signal | Bullish | -0.50% | |
Pocket Pivot | Bullish Swing Setup | -0.50% | |
Outside Day | Range Expansion | -0.50% | |
Wide Bands | Range Expansion | -0.50% | |
Oversold Stochastic | Weakness | -0.50% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 15 hours ago |
Possible Inside Day | about 16 hours ago |
Down 3% | about 20 hours ago |
Down 2 % | about 21 hours ago |
Down 1% | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 04/30/2024
Arrowhead Research Corporation Description
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Organ Systems Molecular Biology Infection Hepatitis B Gene Expression Obesity RNA Rna Interference Apoptosis Chronic Hepatitis B Virus Chronic Hbv Infection Si RNA Small Interfering Rna
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 42.48 |
52 Week Low | 20.67 |
Average Volume | 1,601,618 |
200-Day Moving Average | 30.39 |
50-Day Moving Average | 32.59 |
20-Day Moving Average | 31.28 |
10-Day Moving Average | 30.65 |
Average True Range | 2.02 |
RSI (14) | 40.48 |
ADX | 22.5 |
+DI | 15.84 |
-DI | 26.71 |
Chandelier Exit (Long, 3 ATRs) | 30.66 |
Chandelier Exit (Short, 3 ATRs) | 33.06 |
Upper Bollinger Bands | 36.60 |
Lower Bollinger Band | 25.96 |
Percent B (%b) | 0.2 |
BandWidth | 34.01 |
MACD Line | -0.92 |
MACD Signal Line | -0.33 |
MACD Histogram | -0.5894 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 29.87 | ||||
Resistance 3 (R3) | 29.75 | 29.05 | 29.58 | ||
Resistance 2 (R2) | 29.05 | 28.61 | 29.11 | 29.48 | |
Resistance 1 (R1) | 28.60 | 28.34 | 28.25 | 28.72 | 29.39 |
Pivot Point | 27.90 | 27.90 | 27.73 | 27.96 | 27.90 |
Support 1 (S1) | 27.45 | 27.46 | 27.10 | 27.57 | 26.89 |
Support 2 (S2) | 26.75 | 27.19 | 26.81 | 26.80 | |
Support 3 (S3) | 26.30 | 26.75 | 26.70 | ||
Support 4 (S4) | 26.42 |